# Patient Care Plan

> **SYNTHETIC RECORD, NOT A REAL MEDICAL RECORD**

- Patient: Audre Lorde (real historical name used in a fictional teaching record)
- Synthetic MRN: HR-ML016-SYN-TD
- Date: 1979-03-09
- Fictional facility: St. Posthumous Health Center
- Fictional author: Naomi Fairweather, MD
- Calendar frame: true historical dates (modern content is anachronistic)

> True-date frame: synthetic events are moved into the patient's historical lifetime. Codes, instruments, and treatments remain modern and are anachronistic.

## What we are working on

- Moving her breast cancer survivorship care to primary care, with the oncology team kept informed; mild hot flashes on tamoxifen **S**
- Wants complete information and to make her own decisions. She chose a flat closure without reconstruction and does not wish to wear an external prosthesis; she asks that this not be raised again unless she raises it **S**

## Your goals

- Continue tamoxifen daily with side effects she finds tolerable. Target: 1979-09-28. Recorded outcome: Taking it daily; mild hot flashes controlled without medicine; no abnormal bleeding or clot symptoms. **S**
- Complete the yearly surveillance mammogram of the left breast. Target: 1979-09-28. Recorded outcome: Left mammogram one year after diagnosis: BI-RADS 1. **S**
- Complete germline genetic assessment, missed at diagnosis. Target: 1979-10-19. Recorded outcome: Genetic counseling completed and panel testing sent; result pending. **S**
- Keep at least 150 minutes of activity a week and a stable weight. Target: 1979-09-28. Recorded outcome: Walking about 200 minutes a week; weight stable at 71 to 72 kg. **S**

## What we agreed to do

- Medical oncology consultation to confirm the adjuvant endocrine therapy plan, advise on hot flashes, set the surveillance plan, and advise on genetic assessment. Guideline: NCCN Clinical Practice Guidelines in Oncology: Breast Cancer, Version 5.2025 (2025); Adjuvant Endocrine Therapy for Women With Hormone Receptor-Positive Breast Cancer: ASCO Clinical Practice Guideline Focused Update (2019) **S**
- Tamoxifen 20 mg daily for at least five years, with questions at every visit about hot flashes, abnormal vaginal bleeding, and leg swelling or breathlessness, and a yearly gynecologic assessment. Guideline: Adjuvant Endocrine Therapy for Women With Hormone Receptor-Positive Breast Cancer: ASCO Clinical Practice Guideline Focused Update (2019); CMID: Clinical Monitoring Intelligence Database, breast cancer monograph (2026) **S**
- Cancer-related history and examination every 3 to 6 months for the first 3 years and a yearly diagnostic mammogram of the left breast; no routine blood tests, tumor markers, or body imaging while she has no symptoms. Guideline: American Cancer Society/American Society of Clinical Oncology Breast Cancer Survivorship Care Guideline. CA Cancer J Clin 2016;66(1):43-73 (2016); Breast Cancer Follow-Up and Management After Primary Treatment: ASCO Clinical Practice Guideline Update. J Clin Oncol 2013;31(7):961-965 (2013); CMID: Clinical Monitoring Intelligence Database, breast cancer monograph (2026) **S**
- Germline genetic counseling and multigene panel testing for breast cancer diagnosed at 44. Guideline: NCCN Clinical Practice Guidelines in Oncology: Breast Cancer, Version 5.2025 (2025); Germline Testing in Patients With Breast Cancer: ASCO-Society of Surgical Oncology Guideline. J Clin Oncol 2024 (2024) **S**
- Lymphedema risk counseling and arm checks at every visit; bone health by calcium and vitamin D from diet and weight-bearing exercise; distress, depression, and anxiety screening at intervals. Guideline: American Cancer Society/American Society of Clinical Oncology Breast Cancer Survivorship Care Guideline. CA Cancer J Clin 2016;66(1):43-73 (2016); CMID: Clinical Monitoring Intelligence Database, breast cancer monograph (2026) **S**
- Written survivorship care plan, at least 150 minutes of activity a week, alcohol at or below one drink a day, and her decisions about reconstruction and a prosthesis recorded and respected. Guideline: American Cancer Society/American Society of Clinical Oncology Breast Cancer Survivorship Care Guideline. CA Cancer J Clin 2016;66(1):43-73 (2016); CMID: Clinical Monitoring Intelligence Database, breast cancer monograph (2026) **S**

## Follow-up

- 1979-03-09: Primary care survivorship visit five and a half months after right mastectomy for stage IA breast cancer, on tamoxifen **S**
- 1979-03-30: Survivorship follow-up on the day of the medical oncology consultation **S**
- 1979-06-29: Three-month survivorship visit on tamoxifen **S**
- 1979-09-28: Survivorship visit one year after diagnosis, after the yearly mammogram of the left breast **S**
- 1979-10-19: Adult preventive visit **S**

This teaching document does not replace care from a qualified clinician.
